Parkinsons disease : pharmacotherapy key agents summary

The management of Parkinson's Disease (PD) is a complex, multifaceted process that requires careful consideration of both pharmacological and non-pharmacological strategies to optimize patient outcomes. At the core of managing PD is the goal of alleviating symptoms, improving quality of life (QoL), and minimizing the progression of the disease through tailored therapeutic approaches.

Initially, the referral to a neurologist or geriatrician is crucial to confirm the diagnosis of PD and to consider the need for symptomatic treatment. Early and accurate diagnosis allows for the timely initiation of treatment strategies that can significantly impact the patient's quality of life. The choice of first-line treatment is critical and is usually based on the severity of symptoms, their impact on the patient's quality of life, and individual clinical and lifestyle circumstances.

Levodopa remains the cornerstone of PD treatment for many patients, particularly those in whom symptoms substantially affect quality of life. However, the therapeutic plan may also include Monoamine Oxidase B (MAO-B) inhibitors or dopamine agonists as potential alternatives or complements to Levodopa therapy. The decision to utilize these medications depends on a comprehensive assessment of the patient's preferences, the potential benefits, and the risks associated with each drug class. It is important...